# Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

> **NCT05423769** · — · COMPLETED · sponsor: **Hikma Pharmaceuticals LLC** · enrollment: 30 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod

## Key facts

- **NCT ID:** NCT05423769
- **Lead sponsor:** Hikma Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05423769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05423769, "Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05423769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*